Precede Biosciences

We're excited to announce a new team member, Daniel Karl, PhD, has joined Precede Biosciences as Director, Translational Sciences. #WelcomeAboard #MeetOurTeam

Winship medical oncologist Jacob E. Berchuck, MD recently spoke with Targeted Oncology on how a new epigenomic platform may influence the accessibility of prostate-specific membrane antigen (PSMA)-based therapies, especially for patients who may not have easy access to PSMA PET scans. Learn more ➡️ https://brnw.ch/21wPMdg

Unveiling AI’s Transformative Role in #ProstateCancerCare #PMWC25 AI is redefining prostate cancer diagnostics and treatment, driving a new era of precision medicine. From multimodal AI (#MMAI) algorithms included in the #NCCN Guidelines to cutting-edge imaging tools like #PSMA #PET, the integration of AI is revolutionizing how we understand and treat this disease. Dr. William Oh, prominent prostate oncologist, Yale Cancer Center's PM Director and Chair of PMWC 2025’s AI Models for RWE/D Applications session, shares some exciting advancements: Personalized Treatment with AI: Multimodal AI is now helping risk stratify localized prostate #cancerpatients and determine who benefits most from #hormonetherapy alongside #radiation. The Genomics-AI Connection: As sequencing costs decrease, the fusion of genomics and AI will unlock patterns for truly individualized cancer care. Revolutionary Imaging: AI enhances tools like PSMA PET, allowing #clinicians to quantify disease intensity and guide #radioligand #therapy decisions.  Dr. Oh also highlights AI-driven drug discovery, where real-world evidence and in silico chemistry are uncovering combinations of therapies unimaginable just a few years ago. These groundbreaking innovations are at the heart of PMWC 2025’s Track 2, which will explore how AI can harness real-world evidence to revolutionize healthcare outcomes. And that’s just the beginning. PMWC 2025 features a diverse array of sessions, including: “AI in Radiology and Imaging Applications” (Paul Chang, University of Chicago; Curtis Langlotz; Sharmila Majumdar; Eliot Siegel, VA Maryland Healthcare System; Katherine Andriole, Brigham and Women's Hospital) "How to Implement AI for Faster Readout of Clinical Trials” (Jennifer Webster, Pfizer; Brandon Allgood, Parabilis Medicines; Julian Hong, UCSF; Andrew Roddam, EveryONE Medicines; Michiel JM Niesen, nference) “Leveraging AI and Real-World Evidence to Transform Patient Care” (Amrita Basu, UCSF) “Radiopharmaceuticals for Cancer Therapy” (William Oh, Naga Vara Kishore Pillarsetty, Memorial Sloan Kettering; Jones Nauseef, Convergent Therapeutics, Inc.; Thomas Hope, University of California, San Francisco) “Advancements in Digital Imaging: Enhancing Accuracy in Cancer Diagnostics” (Razelle Kurzrock, Medical College of Wisconsin; Hedvig (Hedi) Hricak; Wafik S. El-Deiry, MD, PhD, FACP, Brown University/WIN) Showcase: J.Carl Barrett (Precede Biosciences): Advancing liquid biopsy innovations for diagnostics. Join Us: Explore these innovations and more at PMWC 2025 (Feb 5-7, Santa Clara Convention Center with 2500 attendees. PMWC 2025 Program: https://lnkd.in/gPtkWZbQ Exact Sciences, Tempus AI, Promaxo, ArteraAI PMWC - Precision Medicine World Conference, Tomasz (Tom) Beer, Eric A. Klein, MD, Dan McCormick, Stacy Loeb, Matt Cooperberg #PMWC25 #PrecisionMedicine #ArtificialIntelligence #ProstateCancer #RealWorldEvidence #CancerDiagnostics #Radiopharmaceuticals #ClinicalTrials #DigitalImaging

🔬 Exciting progress from our portfolio company, Precede Biosciences! At SABCS 2024, Precede presented their novel ER Transcriptional Dependency Index (PERDI), a blood-based test designed to enhance the use of endocrine therapy in ER+ metastatic #BreastCancer.     This innovative approach addresses critical unmet needs in treatment decision-making, with the potential to identify patients who might benefit from monotherapy with emerging oral selective estrogen receptor degraders (SERDs) and antibody-drug conjugates (ADCs).    Learn more about Precede’s impactful work here: https://lnkd.in/dNjPqyYK    #PartnerNews 

Thank you to everyone who stopped by our #SABCS24 poster spotlight presentation with Precede Biosciences' Jonathan Beagan today. We love sharing our science and appreciate the interest in scientific exchange. #LiquidBiopsy #BreastCancer #DrugDevelopment

Precede Biosciences presents a novel ER transcriptional dependency index at #SABCS24 designed to further inform use of endocrine therapy from a simple blood test. View press release: https://bit.ly/41p9HOW #BreastCancer #LiquidBiopsy #DrugDevelopment #SERDs #ADCs

Precede Biosciences’ COO Jennifer Fortune sat down with Tom Froggatt of Singular: Building Brilliant Biotechs to discuss her career journey, words of wisdom for new PhDs, and the game-changing potential of epigenomics in precision medicine. Check out the interview: https://lnkd.in/gbEWdPXy.

Team Precede Biosciences is onsite and ready to mingle at #SABCS24: Say hello to Jonathan Beagan, Corrie Painter, Aparna Gorthi, and J.Carl Barrett. #LiquidBiopsy #DreamTeam

Check out the latest interview with Precede Biosciences' CSO J.Carl Barrett and journalist Caroline Hopkins Legaspi in Precision Medicine Online. (subscription required) #PrecisionMedicine #DrugDevelopment #PSMA #ProstateCancer

This year’s Life Science nominees at the #NEVYs24 are breaking boundaries and changing lives. From early-stage pioneers to industry powerhouses, these companies are paving the way for the future of the life science industry. Here’s a closer look at the awards up for grabs as these contestants prepare to battle it out next week at #NEVYsSurvivor! 🏆 Emerging Life Science Company of the Year 💡 – Visionary early-stage companies with groundbreaking technologies and ambitious teams who are rewriting the rules: Precede Biosciences  ARTBIO  Diagonal Therapeutics  Clasp Therapeutics  Nvelop Therapeutics Powerhouse Life Science Company of the Year 💪 – Resilient companies that have made waves with IPOs, M&As, or transformative deals, amplifying their impact across the ecosystem: Cerevel Therapeutics  Mariana Oncology  Morphic Therapeutic Neumora Learn more about the rest of the nominees here! https://lnkd.in/e7f7mfDZ #NEVCA #Innovation